Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes

Journal of Nuclear Medicine

Volumn 48, Issue 7, 2007, Pages 1180-1189

  McDevitt, Michael R ^a   Chattopadhyay, Debjit ^a   Kappel, Barry J ^a   Jaggi, Jaspreet Singh ^a   Schiffman, Scott R ^a   Antczak, Christophe ^a   Njardarson, Jon T ^b   Brentjens, Renier ^a   Scheinberg, David A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Department of Obstetrics Gynecology   (United States)

Author keywords

DOTA; Nanoconstructs; Nanotechnology; Rituximab; Single walled carbon nanotubes

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; FLUORESCENT DYE; INDIUM 111; METAL CHELATE; METAL ION; MONOCLONAL ANTIBODY; RITUXIMAB; SINGLE WALLED NANOTUBE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER MODEL; CHEMICAL STRUCTURE; CONTROLLED STUDY; COVALENT BOND; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG TARGETING; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; IMMUNOREACTIVITY; ISOTOPE LABELING; LYMPHOMA; MOUSE; NANOTECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; REACTION ANALYSIS; SCID MOUSE; SYNTHESIS; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CELL LINE, TUMOR; CHELATING AGENTS; FEMALE; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; INDIUM RADIOISOTOPES; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; MICE, SCID; NANOTUBES, CARBON; NEOPLASM TRANSPLANTATION; RADIOPHARMACEUTICALS; SOLUBILITY; TRANSPLANTATION, HETEROLOGOUS;

EID: 34447329851     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.106.039131     Document Type: Article

References (40)

1. Hartgerink JD, Beniash E, Stupp SI. Peptide-amphiphile nanofibers: a versatile scaffold for the preparation of self-assembling materials. Proc Natl Acad Sci U S A. 2002;99:5133-5138.
2. Pastorin G, Wu W, Wieckowski S, et al. Double functionalization of carbon nanotubes for multimodal drug delivery. Chem Commun (Camb). 2006;11:1182-1184.
3. in het Panhuis M. Vaccine delivery by carbon nanotubes. Chem Biol. 2003;10: 897-898.
4. Shi Kam NW, Jessop TC, Wender PA, Dai HJ. Nanotube molecular transporters: internalization of carbon nanotube-protein conjugates into mammalian cells. J Am Chem Soc. 2004;126:6850-6851.
5. Pantarotto D, Briand JP, Prato M, Bianco A. Translocation of bioactive peptides across cell membranes by carbon nanotubes. Chem Commun (Camb). 2004; 7:16-17.
6. Bianco A, Hoebeke J, Godefroy S, et al. Cationic carbon nanotubes bind to CpG oligodeoxynucleotides and enhance their immunostimulatory properties. J Am Chem Soc. 2005;127:58-59.
7. Cherukuri P, Bachilo SM, Litovsky SH, Weisman RB. Near-infrared fluorescence microscopy of single-walled carbon nanotubes in phagocytic cells. J Am Chem Soc. 2004;126:15638-15639.
8. Dresselhaus MS, Avouris P. Introduction to carbon materials research. Top Appl Phys. 2001;80:1-9.
9. Majoros IJ, Myc A, Thomas T, Mehta CB, Baker JR Jr. PAMAM dendrimerbased multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality. Biomacromolecules. 2006;7:572-579.
10. Patri AK, Myc A, Beals J, et al. Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjug Chem. 2004;15:1174-1181.
11. Talanov VS, Regino CA, Kobayashi H, Bernardo M, Choyke PL, Brechbiel MW. Dendrimer-based nanoprobe for dual modality magnetic resonance and fluorescence imaging. Natto Lett. 2006;6:1459-1463.
12. Nikula TK, Bocchia M, Curcio MJ, et al. Impact of the high tyrosine fraction in complementary determining regions: measured and predicted effects of radioiodination on IgG radioimmunotherapy. Mol Immunol. 1995;32:865-872.
13. Hamblett KJ, Senter PD, Chace DF. Effects of drug loading on the antitumor activity of a monoclonal antibody drug composite. Clin Cancer Res. 2004;10: 7063-7070.
14. Kam NW, O'Connell M, Wisdom JA, Dai HJ. Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. Proc Natl Acad Sci U S A. 2005;102:11600-11605.
15. Shvedova AA, Castranova V, Kisin ER, et al. Exposure to carbon nanotube material: assessment of nanotube cytotoxicity using human keratinocyte cells. J Toxicol Environ Health A. 2003;66:1909-1926.
16. Nel A, Xia T, Madler L, Li N. Toxic potential of materials at the nanolevel. Science. 2006;311:622-627.
17. Sayes CM, Liang F, Hudson J.L, et al. Functionalization density dependence of single-walled carbon nanotubes cytotoxicity in vitro. Toxicol Lett. 2006;161: 135-142.
18. Dumortier H, Lacotte S, Pastorin G, et al. Functionalized carbon nanotubes are non-cytotoxic and preserve the functionality of primary immune cells. Nano Lett. 2006;6:1522-1528.
19. Wang H, Wang J, Deng X, et al. Biodistribution of carbon single-wall nanotubes in mice. J Nanosci Nanotechnol. 2004;4:1019-1024.
20. Singh R, Pantarotto D, Lacerda L, et al. Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. Proc Natl Acad Sci U S A. 2006;109:3357-3362.
21. Mammen M, Choi SK, Whitesides GM. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed Engl. 1998;37:2755-2794.
22. Chattopadhyay D, Galeska I, Papadimitrakopoulos F. Complete elimination of metal catalysts from single wall carbon nanotubes. Carbon. 2002;40: 985-988.
23. Georgakilas V, Tagmatarchis N, Pantarotto D, Bianco A, Briand JP, Prato M. Amino acid functionalisation of water soluble carbon nanotubes. Chem Commun. 2002;12:3050-3051.
24. Sarin VK, Kent SBH, Tam JP, Merrifield RB. Quantitative monitoring of solid-phase peptide synthesis by ninhydrin reaction. Anal Biochem. 1981;117: 147-157.
25. McDevitt MR, Ma D, Lai LT, et al. Tumor therapy with targeted atomic nanogenerators. Science. 2001;294:1537-1540.
26. Nikula TK, Curcio MJ, Brechbiel MW, Gansow OA, Finn RD, Scheinberg DA. A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies. Nucl Med Biol. 1995;22:387-390.
27. Dadachova E, Chappell LL, Brechbiel MW. Spectrophotometric method for determination of bifunctional macrocyclic ligands in macrocyclic ligand-protein conjugates. Nucl Med Biol. 1999;26:977-982.
28. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959;82:70-77.
29. 225Ac radioimmunopharmaceuticals. Appl Radial Isot. 2002;57:841-847.
30. Latouche JB, Sadelain M. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Nat Biotechnol. 2000;18:405-409.
31. Riviere I, Brose K, Mulligan RC. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci U S A. 1995;92:6733-6737.
32. Terwey TH, Kim TD, Kochman AA, et al. CCR2 is required for CD8-induced graft-versus-host disease. Blood. 2005;106:3322-3330.
33. Ghetie MA, Richarson J, Tucker T, Jones D, Uhr JW, Vitetta ES. Disseminated or localized growth of a human B-cell tumor (Daudi) in scid mice. Int J Cancer. 1990;45:481-485.
34. 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies. Leukemia. 2002;16:60-66.
35. Esteban JM, Schlom J, Gansow OA, et al. New method for the chelation of indium-111 to monoclonal antibodies: biodistribution and imaging of athymic mice bearing human colon carcinoma xenografts. J Nucl Med. 1987;28: 861-870.
36. Ruegg CL, Anderson-Berg WT, Brechbiel MW, Mirzadeh S, Gansow OA, Strand M. Improved in vivo stability and tumor targeting of bismuth-labeled antibody. Cancer Res. 1990;50:4221-4226.
37. Shukla R, Thomas TP, Peters JL, et al. HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb. Bioconjug Chem. 2006;17:1109-1115.
38. Sharkey RM, Primus FJ, Goldenberg DM. Second antibody clearance of radiolabeled antibody in cancer radioimmunodetection. Proc Natl Acad Sci U S A. 1984;81:2843-2846.
39. Mueller BM, Reisfeld RA, Gillies SD. Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2. Proc Natl Acad Sci U S A. 1990;87:5702-5705.
40. Kok RJ, Schraa AJ, Bos EJ, et al. Preparation and functional evaluation of RGD-modified proteins as αvβ3 integrin directed therapeutics. Bioconjug Chem. 2002;13:128-135.